Pediatrics Book



Aka: Pemoline, Cylert
  1. See Also
    1. Attention Deficit Disorder in Children
    2. School Problem Evaluation
    3. Attention Deficit Disorder in Adults
    4. ADHD Diagnosis
    5. ADHD Differential Diagnosis
    6. ADHD Comorbid Conditions
    7. ADHD Non-Pharmacologic Management
    8. ADHD Medications
    9. Dextroamphetamine (Dexedrine, Dextrostat, Adderall) or Lisdexamfetamine (Vyvanse)
    10. Methylphenidate (Ritalin, Methylin, Concerta)
    11. Atomoxetine (Strattera)
  2. Indications
    1. Attention Deficit Hyperactivity Disorder (ADHD)
      1. No longer available in United States
      2. Not recommended for use due to hepatotoxicty
  3. Pharmacokinetics
    1. Onset: 2 hours
    2. Duration: 6 to 10 hours
    3. Steady state reached in 2 to 3 days
    4. Titrate dose every 3 to 4 weeks
  4. Dosing
    1. Range: 0.5 - 2.5 mg/kg/dose (Up to 112.5 mg/day)
    2. Start: 18.75 mg PO qAM
    3. Frequency: Once to twice daily
  5. Monitoring
    1. Alanine Aminotransferase (ALT)
      1. Obtain baseline
      2. Repeat testing every 2 weeks
    2. Symptom inquiry at every visit
      1. Anorexia
      2. Malaise
      3. Gastrointestinal symptoms
      4. Dark Urine
  6. Precautions
    1. Informed Consent from parents required prior to use
  7. Adverse Effects
    1. Hepatic failure of dysfunction
    2. Choreoathetoid movements
    3. Other adverse effects similar to Methylphenidate
  8. References
    1. (1996) Pediatrics 98:301-4 [PubMed]
    2. Andesman (1999) Pediatr Clin North Am 46:945-63 [PubMed]
    3. Bennett (1999) Pediatr Clin North Am 46:929-44 [PubMed]
    4. Challman (2000) Mayo Clin Proc 75:711-21 [PubMed]

Pemoline (C0030800)

Definition (NCI) An oxazolidine compound with central nervous system (CNS) stimulant property. Although pemoline has pharmacological activity similar to other CNS stimulants, the exact mechanism and site of action are unknown. This agent has minimal sympathomimetic properties, but animal studies indicate it may work through dopaminergic mechanisms. Pemoline has been withdrawn from the U.S. market because of the agent's association with life threatening hepatic failure.
Definition (MSH) A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D010389
SnomedCT 387393000, 70776005
LNC LP16236-9, MTHU015176
English Phenoxazole, Phenylisohydantoin, pemoline, 4(5H)-Oxazolone, 2-amino-5-phenyl-, 2-Imino-4-keto-5-phenyltetrahydrooxazole, 5-Phenylisohydantion, pemoline (medication), Pemoline, Pemoline [Chemical/Ingredient], pio, PIO, Pemoline (product), Pemoline (substance), PEMOLINE
Swedish Pemolin
Czech pemolin
Finnish Pemoliini
Polish Pemolina
Japanese フェニルイソヒダントイン, ペモリン, フェノキサゾル, ベタナミン
Spanish fenilisohidantoína, pemolina (producto), pemolina (sustancia), pemolina, Fenilisohidantoina, Fenoxazol, Pemolina
French Pemoline
German Pemolin, Phenoxazol, Phenylisohydantoin
Italian Pemolina
Portuguese Fenilisoidantoína, Fenoxazol, Pemolina
Derived from the NIH UMLS (Unified Medical Language System)

Cylert (C0719594)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D010389
English cylert, Cylert, Abbott Brand of Pemoline
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree